Abstract
One of the major neuropathological changes characteristic of Alzheimer’s disease (AD) is deposits of beta-amyloid plaques and neurofibrillary tangles in neocortical and subcortical regions of the AD brain. The histochemical detection of these lesions in postmortem brain tissue is necessary for definitive diagnosis of AD. Methods for their in vivo detection would greatly aid the diagnosis of AD in early stages when neuronal loss and related functional impairment are still limited and would also open the opportunity for effective therapeutic interventions. Magnetic resonance imaging (MRI) theoretically provides the spatial resolution needed to resolve amyloid-β plaques. Although currently limited for clinical applications due to unfavorable long acquisition times, MRI has been used to visualize Aβ plaques in AD mouse models. The ability to detect amyloid-positive brain lesions in vivo using non-invasive imaging would allow to track disease progression and to monitor the efficacy of potential therapies in disease-modifying studies using transgenic models resembling AD pathology. Here, we provide MRI protocols for in vivo (mouse) and ex vivo (AD tissue samples) amyloid plaque imaging and the procedure for correlating these with thioflavin-S and iron-staining histology. Current challenges and limitations are discussed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Selkoe, D. J. Alzheimer’s disease: Genes, proteins, and therapy. Physiol Rev 2001;81:741–766.
Klunk, W. E., Lopresti, B. J., Ikonomovic, M. D., Lefterov, I. M., Koldamova, R. P. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer’s disease brain but not in transgenic mouse brain. J Neurosci 2005;25:10598–10606.
Meyer-Luehmann, M., Spires-Jones, T. L., Prada, C. et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer’s disease. Nature 2008;451(7179):720–724.
Guentert, A., Doebeli, H., Bohrmann, B. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 2006;143:461–475.
Kuo, Y. M., Kokjohn, T. A., Beach, T. G. et al. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer’s disease brains. J Biol Chem 2001;276:12991–12998.
Connor, J. R., Menzies, S. L., St. Martin, S. M., Mufson, E. J. A histochemical study of iron, transferrin and ferritin in Alzheimer’s diseased brains. J Neurosci Res 1992;31:75–83.
Meadowcroft, M. D., Connor, J. R., Smith, M. B., Yang, Q. X. MRI and histological analysis of Beta-Amyloid Plaques in both human Alzheimer’s disease and APP/PS1 transgenic mice. J Magn Reson Imaging 2009;29:997–1007.
Benveniste, H., Einstein, G., Kim, K. R., Hulette, C., Johnson, G. A. Detection of neuritic plaques in Alzheimer’s disease by magnetic resonance microscopy. Proc Natl Acad Sci USA 1999;96:14079.
Dhenain, M., Privat, N., Duyckaerts, C., Jacobs, R. E. Senile plaques do not induce susceptibility effects in T2*-weighted MR microscopic images. NMR Biomed 2002;15:197–203.
Poduslo, J. F., Wengenack, T. M., Curran, G. L. et al. Molecular targeting of Alzheimer’s amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis 2002;11:315–329.
Rudin, M., Mueggler, T., Allegrini, P. R., Baumann, D., Rausch, M. Characterization of CNS disorders and evaluation of therapy using structural and functional MRI. Anal Bioanal Chem 2003;377:973–981.
Helpern, J. A., Lee, S. P., Falangola, M. F. et al. MRI assessment of neuropathology in a transgenic mouse model of Alzheimer’s disease. Magn Reson Med 2004;51(4):794–798.
Lee, S. P., Falangola, M. F., Nixon, R. A., Duff, K., Helpern, J. A. Visualization of beta-amyloid plaques in a transgenic mouse model of Alzheimer’s disease using MR microscopy without contrast reagents. Magn Reson Med 2004;52:538–544.
Zhang, J., Yarowsky, P., Gordon, M. N. et al. Detection of amyloid plaques in mouse models of Alzheimer’s disease by magnetic resonance imaging. Magn Reson Med 2004;51:452–457.
Jack, C. R., Jr, Garwood, M., Wengenack, T. M. et al. In vivo visualization of Alzheimer’s amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn Reson Med 2004;52:1263–1271.
Vanhoutte, G., Dewachter, I., Borghgraef, P., Van Leuven, F., Van der Linden, A. Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer’s disease. Magn Reson Med 2005;53(3):607–613.
Jack, C. R., Jr, Wengenack, T. M., Reyes, D. A. et al. In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer’s transgenic mice. J Neurosci 2005;25(43):10041–10048.
Jack, C. R., Jr, Marjanska, M., Wengenack, T. M. et al. Magnetic resonance imaging of Alzheimer’s pathology in the brains of living transgenic mice: A new tool in Alzheimer’s disease research. Neuroscientist 2007;13(1):38–48.
Wadghiri, Y. Z., Sigurdsson, E. M., Sadowski, M. et al. Detection of Alzheimer’s amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med 2003;50:293–302.
Higuchi, M., Iwata, N., Matsuba, Y., Sato, K., Sasamoto, K., Saido, T. C. 19F and 1H MRI detection of amyloid b plaques in vivo. Nat Neurosci 2005;8:527–533.
Higgins, G. A., Jacobsen, H. Transgenic mouse models of Alzheimer’s disease: Phenotype and application. Behav Pharmacol 2003;14:419–438.
Ramakrishnan, M., Wengenack, T. M., Kandimalla, K. K., Poduslo, J. F. et al. Selective contrast enhancement of individual Alzheimer’s disease amyloid plaques using a polyamine and Gd-DOTA conjugated antibody fragment against fibrillar Abeta42 for magnetic resonance molecular imaging. Pharm Res 2008;25(8):1861–1872.
Wengenack, T. M., Jack, C. R., Jr., Garwood, M., Poduslo, J. F. MR microimaging of amyloid plaques in Alzheimer’s disease transgenic mice. Eur J Nucl Med Mol Imaging 2008;35(Suppl 1):S82–S88.
Poduslo, J. F., Ramakrishnan, M., Holasek, S. S. et al. In vivo targeting of antibody fragments to the nervous system for Alzheimer’s disease immunotherapy and molecular imaging of amyloid plaques. J Neurochem 2007;102(2):420–433.
Braakman, N., Matysik, J., van Duinen, S. G. et al. Longitudinal assessment of Alzheimer’s β-Amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging. J Magn Reson Imaging 2006;24:530–536.
Meadowcroft, M. D., Zhang, S., Liu, W. et al. Direct magnetic resonance imaging of histological tissue samples at 3.0T. Magn Reson Med 2007;57:835–841.
Hildebrandt, I. J., Su, H., Weber, W. A. Anesthesia and other considerations for in vivo imaging of small animals. ILAR J 2008;49(1):17–26.
Chamberlain, R., Reyes, D., Curran, G. L. et al. Comparison of amyloid plaque contrast generated by T2-Weighted, T*2-weighted, and susceptibility-weighted imaging methods in transgenic mouse models of Alzheimer’s disease. Magn Reson Med 2009;61:1158–1164.
Paxinos, G., Franklin, K. B. J. The Mouse Brain in Stereotaxic Coordinates. San Diego, CA: Academic Press; 2001.
Muskulus, M., Scheenstra, A. E. H., Braakman, N. et al. Prospects for early detection of Alzheimer’s disease from serial MR images in transgenic mouse models. Curr Alzheimer Res 2009;6:503–518.
Braak, H., Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–259.
Sigurdsson, E. M. Histological staining of amyloid-beta in mouse brains. Methods Mol Biol 2005;299:299–308.
Baltes, C., Radzwill, N., Bosshard, S., Marek, D., Micro, R. M. MR imaging of the mouse brain using a novel 400 MHz cryogenic quadrature RF probe. NMR Biomed 2009;22(8):834–842.
Games, D., Adams, D., Alessandrini, R. et al. Alzheimer-type neuropathology in transgenic mice over-expressing V717F beta-amyloid precursor protein. Nature 1995;373:523–527.
Moechars, D., Dewachter, I., Lorent, K. et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 1999;274(10):6483–6492.
Hsiao, K., Chapman, P., Nilsen, S. et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996;274:99–102.
Sturchler-Pierrat, C., Abramowski, D., Duke, M. et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 1997;94:13287–13292.
Holcomb, L., Gordon, M. N., Accelerated, Mc. G. E. Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998;4:97–100.
Richards, J. G., Higgins, G. A., Ouagazzal, A. M. et al. PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci 2003;23:8989–9003.
Acknowledgments
The author would like to thank Dr. Irene Knüsel and Dr. Martin Herzig for careful reading of the manuscript and providing their comments on AD mouse models and histology.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Baltes, C., Princz-Kranz, F., Rudin, M., Mueggler, T. (2011). Detecting Amyloid-β Plaques in Alzheimer’s Disease. In: Modo, M., Bulte, J. (eds) Magnetic Resonance Neuroimaging. Methods in Molecular Biology, vol 711. Humana Press. https://doi.org/10.1007/978-1-61737-992-5_26
Download citation
DOI: https://doi.org/10.1007/978-1-61737-992-5_26
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61737-991-8
Online ISBN: 978-1-61737-992-5
eBook Packages: Springer Protocols